NV
Nandini verma
Advanced Centre for Treatment Research and Education in Cancer, Institute of Genomics and Integrative Biology CSIR
0000-0001-5260-8999
Employment
-
Advanced Centre for Treatment Research and Education in Cancer Principal Investigator2019 - Present
Education
-
Institute of Genomics and Integrative Biology CSIR Dr.2005 - 2011
Projects & Funding
Projects & funding information is unavailable.
Publications (27)
- Abstract 5663: Chemotherapy-induced galectin-1 derives drug-tolerant persister state associated EMT in triple negative breast cancer with targetable vulnerability to ferroptosis inducers. Save
- Editorial: p53 in cancer therapy: the impact of mutations on the genome guardian Save
- The Role of BRD4 in Acquiring Drug-Tolerant Persister (DTP) Phenotype in Different Subtypes of TNBC Save
- Low-GPX4 drives a sustained drug-tolerant persister state in TNBC by a targetable adaptive FSP1 upregulation. Save
- Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas. Save
- EGFR-to-Src family tyrosine kinase switching in proliferating-DTP TNBC cells creates a hyperphosphorylation-dependent vulnerability to EGFR TKI Save
- Inhibiting de novo lipogenesis identifies a therapeutic vulnerability in therapy-resistant colorectal cancer. Save
- Understanding the Role of Therapy-Induced Secretome in Chemo-resistance and EMT in Triple-Negative Breast Cancer Save
- EGFR-to-Src family tyrosine kinase switching in proliferating-DTP TNBC cells creates a hyperphosphorylation-dependent vulnerability to EGFR TKI Save
- Who dictates and when: Genetic and epigenetic dictatorships in breast cancer response and resistance to therapy Save